What was the key results of the analysis?

Men taking enzalutamide had smaller RNA signatures than those on active surveillance. The researchers found that men with certain RNA signatures benefited more from taking enzalutamide. The researchers found that men with certain RNA signatures benefited more from taking enzalutamide. The researchers also found that men with higher levels of a biomarker called androgen receptor activity (AR-A) were more likely to benefit from enzalutamide.

What were the key results of the analysis?

- Men taking enzalutamide had smaller RNA signatures than those on active surveillance.
- The researchers found that men with certain RNA signatures benefited more from taking enzalutamide.
- The researchers also found that men with higher levels of a biomarker called androgen receptor activity (AR-A) were more likely to benefit from enzalutamide.

What were the main conclusions reported in the scientific abstract?

Based on the key results of the analysis, the researchers concluded that:

1. Men taking enzalutamide had smaller RNA signatures than those on active surveillance.
2. Men with certain RNA signatures benefited more from taking enzalutamide.
3. Men with higher levels of a biomarker called androgen receptor activity (AR-A) were more likely to benefit from enzalutamide.

Who sponsored this study?

The study was sponsored by Astellas. The sponsors would like to thank all of the men who took part in this study.